Source: CureToday articles
IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell.
Recent Content
- IDH Inhibitors Offer New, Safer Option for Some Brain Tumors
- What I Learned From My Cancer Nurse Maria
- Helping the Team While Helping Others
- Christian John Lillis on C diff, Public Health, and the Role of Pharmacists
- Teaching, Writing, Healing: The Intersections of My Cancer Journey
- Market Access: A Unique Career Path for Pharmacists
- Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
- Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review
- True Grit: The Spirit of an Extraordinary Healer
- Physical Activity Can Improve Quality of Life in Patients With Newly Diagnosed Multiple Myeloma